Abstracts tagged "Biologics"

Abstract Number: L12 • 2019 ACR/ARP Annual Meeting
Safety and Efficacy of Olokizumab in a Phase III Trial of Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate – CREDO1 Study
Evgeniy Nasonov ¹, Saeed Fatenejad ², Elena Korneva ³, Diana Krechikova ⁴, Alexey Maslyansky ⁵, Tatyana Plaksina ⁶, Marina Stanislav ⁷, Rumen Stoilov ⁸, Tamara Tyabut ⁹, Sergey Yakushin ¹⁰, Elena Zonova ¹¹ and Mark Genovese¹², ¹FSBSI "Scientific Research Institute of Rheumatology n.a. V.A. Nasonova", Moscow, Russia, ²SFC Medica, Charlotte, North Carolina, ³R-Pharm, Moscow, Russia, ⁴Non-governmental Healthcare Institution "Regional Clinical Hospital at Smolensk station of OJSC "Russian Railways, Smolensk, Russia, ⁵SBHI "North-West Federal Medical Research Center n.a. V.A.Almazov" of the Ministry of Healthcare of the Russian Federation, St-Petersburg, Russia, ⁶SBHI of Nizhny Novgorod Region "Nizhny Novgorod Regional Clinical Hospital n.a. P.A.Semashko", N.Novgorod, Russia, ⁷V.A. Nasonova Research Rheumatology Institute, Moscow, Russia, ⁸UMHAT St. Ivan Rilski, Clinic of Rheumatology, Sofia, Bulgaria, ⁹Belarusian Medical Academy of Postgraduate Education, City Clinical Hospital N1, Minsk, Belarus, ¹⁰Ryazan State Medical University, Ryazan, Russia, ¹¹Novosibirsk State Medical University, State Clinical Polyclinic 1, Novosibirsk, Russia, ¹²Stanford University, Stanford, CA
Background/Purpose: Olokizumab (OKZ) is a new humanized monoclonal antibody targeting IL-6 1, 2. Here we present the results of the first phase III study of…
Abstract Number: L13 • 2019 ACR/ARP Annual Meeting
Guselkumab, an Anti-interleukin-23p19 Monoclonal Antibody, in Biologic-naïve Patients with Active Psoriatic Arthritis: Week 24 Results of the Phase 3, Randomized, Double-blind, Placebo-controlled Study
Philip J. Mease¹, Proton Rahman ², Alice B. Gottlieb ³, Elizabeth Hsia ⁴, Alexa Kollmeier ⁵, Xie Xu ⁶, Ramanand Subramanian ⁵, Prasheen Agarwal ⁵, Shihong Sheng ⁵, Bei Zhou ⁵, Désirée van der Heijde ⁷ and Iain McInnes ⁸, ¹Swedish Medical Center and University of Washington, Seattle, Washington, ²Memorial University of Newfoundland, Newfoundland, Canada, ³Icahn School of Medicine at Mt Sinai, NY, NY, New York, New York, ⁴Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, Pennsylvania, ⁵Janssen Research & Development, LLC, Spring House, Pennsylvania, ⁶Janssen Research & Development, LLC, Spring House, ⁷Leiden University Medical Center, Leiden, Netherlands, ⁸Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Guselkumab (GUS), an anti-interleukin-23p19 monoclonal antibody, is approved for psoriasis (PsO). We assessed GUS efficacy and safety in DISCOVER-1 (ACR2019 Abstract ID697955) and DISCOVER-2,…
Abstract Number: L17 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Anifrolumab in Patients with Moderate to Severe Systemic Lupus Erythematosus: Results of the Second Phase 3 Randomized Controlled Trial
Eric Morand¹, Richard Furie ², Yoshiya Tanaka ³, Ian Bruce ⁴, Anca Askanase ⁵, Christophe Richez ⁶, Sang-Cheol Bae ⁷, Philip Brohawn ⁸, Lilia Pineda ⁹, Anna Berglind ¹⁰ and Raj Tummala ⁹, ¹Monash University, Melbourne, Victoria, Australia, ²Zucker School of Medicine at Hofstra/Northwell, New York, ³University of Occupational and Environmental Health, Kitakyushu, Japan, ⁴University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom, ⁵Columbia University, New York, ⁶CHU de Bordeaux-GH Pellegrin, Bordeaux, France, ⁷Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁸Former employee of AstraZeneca, Gaithersburg, Maryland, ⁹AstraZeneca, Gaithersburg, Maryland, ¹⁰AstraZeneca, Gothenburg, Sweden
Background/Purpose: Anifrolumab, a human monoclonal antibody to the type I IFN receptor subunit 1, had robust efficacy in a phase 2 study in patients with…
Abstract Number: 259 • 2019 ACR/ARP Annual Meeting
Describing Treatment Patterns and Healthcare Costs in Newly Diagnosed Psoriatic Arthritis Patients by Physician Specialty
Joseph Tkacz ¹, Ervant Maksabedian², Philip Chan ¹, Brendan Limone ¹, Alexis Ogdie ³, Elaine Karis ⁴ and Bradley Stolshek ², ¹IBM Watson, Bethesda, MD, ²Amgen Inc., Thousand Oaks, CA, ³University of Pennsylvania, Philadelphia, PA, ⁴Amgen Inc, Thousand Oaks, CA
Background/Purpose: The clinical heterogeneity of psoriatic arthritis (PsA) presents a variety of diagnostic and treatment challenges, which may be reflected in the way different health…
Abstract Number: 1818 • 2019 ACR/ARP Annual Meeting
Continuing versus Withdrawing Ixekizumab in Patients with Psoriatic Arthritis Who Achieved Sustained Minimal Disease Activity: Results from the SPIRIT-P3 Study
Laura Coates¹, Sreekumar Pillai ², Lu Zhang ², David Adams ², Lisa Kerr ², Maja Hojnik ², Gaia Gallo ², Ivo Valter ³, Hasan Tahir ⁴, Vinod Chandran ⁵, Philip Mease ⁶ and Arthur Kavanaugh ⁷, ¹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²Eli Lilly and Company, Indianapolis, IN, ³Center for Clinical and Basic Research, Tallinn, Estonia, ⁴Department of Rheumatology, Whipps Cross University Hospital, London, United Kingdom, ⁵Division of Rheumatology, University of Toronto, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ⁶Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ⁷University of California, San Diego School of Medicine, La Jolla, CA
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory disease that may lead to serious disability if not appropriately treated. Data on the effect of treatment…
Abstract Number: 2711 • 2019 ACR/ARP Annual Meeting
Utilization of Biologic Treatments in Oligoarticular and Polyarticular Juvenile Idiopathic Arthritis
Daniah Basodan¹, Kathleen M Andersen ², Xintong Li ³, Jeffrey Curtis ⁴ and G. Caleb Alexander ⁵, ¹University of Alberta, Edmonton, AB, Canada, ²Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health,, Baltimore, MD, ³Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Johns Hopkins Bloomberg School of Public Health. Center for Drug Safety and Effectiveness, Baltimore, MD
Background/Purpose: In recent years, juvenile idiopathic arthritis (JIA) treatment options have expanded to include biologics such as tumor necrosis factor inhibitors (TNFi) and non-TNF inhibitors…
Abstract Number: 526 • 2019 ACR/ARP Annual Meeting
Factors Influencing Discontinuation in Long-term RA Treatment
Madison Grinnell¹, Sofia Pedro ² and Kaleb Michaud ³, ¹University of Nebraska College of Medicine, OMAHA, NE, ²FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS, ³University of Nebraska Medical Center, Omaha, NE
Background/Purpose: While medication persistence can act as a substitute metric for effectiveness, few studies have examined real-world patterns of bDMARD persistence by line of treatment…
Abstract Number: 1836 • 2019 ACR/ARP Annual Meeting
Clinical Outcomes of Patients with Giant Cell Arteritis with Polymyalgia Symptoms Only vs Cranial Symptoms Only Treated with Tocilizumab or Placebo in a Randomized Clinical Trial
Robert Spiera¹, Sebastian Unizony ², Min Bao ³, Yves Luder ⁴, Páris Sidiropoulos ³, Jian Han ³, Jinglan Pei ³ and John Stone ², ¹Hospital for Special Surgery, New York, NY, ²Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ³Genentech, South San Francisco, CA, ⁴F. Hoffmann-La Roche, Basel, Switzerland
Background/Purpose: GiACTA, a randomized, double-blind, placebo (PBO)–controlled study, demonstrated the efficacy and safety of tocilizumab (TCZ) in patients with giant cell arteritis (GCA).1 Growing evidence…
Abstract Number: 2881 • 2019 ACR/ARP Annual Meeting
Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Psoriatic Arthritis: Disease Activity and Remission in a 48-Week Phase 2b, Randomized, Double‑Blind, Placebo-Controlled, Dose-Ranging Study
Philip Mease¹, Laure Gossec ², Laura Coates ³, Alice B. Gottlieb ⁴, Deepak Assudani ⁵, Barbara Ink ⁵, Jason Coarse ⁶, Oscar Irvin-Sellers ⁵ and Dafna Gladman ⁷, ¹Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, ²Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France, ³University of Oxford, Oxford, United Kingdom, ⁴Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA, Philadelphia, PA, ⁵UCB Pharma, Slough, UK, Slough, United Kingdom, ⁶UCB Pharma, Raleigh, NC, USA, Raleigh, NC, ⁷Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada
Background/Purpose: The ultimate goal of therapy in patients with psoriatic arthritis (PsA) is clinical remission, defined as ‘the absence of clinical and laboratory evidence of…
Abstract Number: 849 • 2019 ACR/ARP Annual Meeting
Risk of Malignancies Associated with Biologics in Rheumatoid Arthritis: Analysis of a National Claim Database
Raphaèle Seror¹, Alexandre Lafourcade ², yann De Rycke ², Bruno Fautrel ³, Xavier Mariette ⁴ and Florence Tubach ⁵, ¹Université Paris Sud, Hôpitaux Universitaires Paris-Sud, AP-HP, INSERM UMR 1184, Le Kremlin-Bicêtre, France, ²Biostatistics, Public Health and Medical Information department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France, Paris, France, ³Pitié-Salpêtrière Hospital, Department of Rheumatology, AP-HP, Sorbonne University, UPMC university, Paris, Ile-de-France, France, ⁴Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France, ⁵Pitié Salpétrière University-Hospital, Paris, Ile-de-France, France
Background/Purpose: Our objectives were to estimate and compare the incidence rate of malignancies between biologic and csDMARD-treated RA patients.Methods: We conducted an historical cohort study…
Abstract Number: 2097 • 2019 ACR/ARP Annual Meeting
Tuberculin Skin Test and Quantiferon®-TB Gold In-Tube Test for Latent Tuberculosis Before Biologic Treatments: Lower Agreement Rate in Spondyloarthropathies Compared to Rheumatoid Arthritis
Ufuk İlgen¹, Sezin Turan ¹, Hakan Emmungil ¹, Alper Sarı ², Abdulsamet Erden ², Levent Kilic ³, Ömer Karadağ ², Sedat Kiraz ³, Ali İhsan Ertenli ⁴, Orhan Küçükşahin ⁵, Şükran Erten ⁶, Zeynel Abidin Akar ⁷, Burak Öz ⁷, Süleyman Serdar Koca ⁸, Cemal Bes ⁹, Nilufer Alpay-Kanitez ¹⁰, Emre Tekgöz ¹¹, Seda Çolak ¹¹, Muhammet Çınar ¹¹, Sedat Yılmaz ¹¹, Veli Yazısız ¹², Mustafa Ender Terzioğlu ¹², Ayşe Bahar Keleşoğlu Dinçer ¹³, Aşkın Ateş ¹³, Rıdvan Mercan ¹⁴, Onay Gercik ¹⁵, Servet Akar ¹⁶, Mehmet Pamir Atagündüz ¹⁷, Gezmiş Kimyon ¹⁸, Emel Gönüllü ¹⁹, Emine Duygu Ersözlü ²⁰, Müge Aydın Tufan ²¹, Burcu Yağız ²², Belkıs Nihan Coşkun ²³, Yavuz Pehlivan ²², Ediz Dalkılıç ²² and Umut Kalyoncu ²⁴, ¹Trakya University, Edirne, Turkey, ²Hacettepe University, Ankara, Turkey, ³Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ⁴Hacettepe University Vasculitis Centre, Ankara, Turkey, Ankara, Turkey, ⁵Liv Hospital, Ankara, Turkey, ⁶Yıldırım Beyazıt University, Ankara, Turkey, ⁷Fırat University, Elazığ, Turkey, ⁸Fırat University School of Medicine Division of Rheumatology, Elazığ, Turkey, ⁹University of Medical Sciences, İstanbul, Turkey, ¹⁰Koc University School of Medicine, Division of Rheumatology, İstanbul, Turkey, ¹¹University of Medical Sciences, Ankara, Turkey, ¹²Akdeniz University, Antalya, Turkey, ¹³Ankara University, Ankara, Turkey, ¹⁴Namık Kemal University, Tekirdağ, Turkey, ¹⁵Izmir Katip Celebi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, İzmir, Turkey, ¹⁶Izmir Katip Celebi University, Faculty of Medicine, Division of Rheumatology, İzmir, Turkey, ¹⁷Marmara University, İstanbul, Turkey, ¹⁸Mustafa Kemal University, Hatay, Turkey, ¹⁹Sakarya University, Sakarya, Turkey, ²⁰Adana State Hospital, Adana, Turkey, ²¹Başkent University, Adana, Turkey, ²²Uludağ University, Bursa, Turkey, ²³Uludağ University, Bursa, ²⁴Hacettepe University Department of Rheumatology, Ankara, Turkey
Background/Purpose: Screening for and the treatment of latent tuberculosis is recommended in patients with inflammatory arthritides prior to biologic treatments, particularly the TNF inhibitors. The…
Abstract Number: 894 • 2019 ACR/ARP Annual Meeting
Frequency, Severity and Costs of Flares Increase with Disease Severity in Newly Diagnosed Systematic Lupus Erythematous: A Real-World Cohort Study, United States, 2004–2015
Miao Jiang ¹, Barnabas Desta ¹, Aimee Near ², Xia Wang ¹ and Edward Hammond¹, ¹AstraZeneca, Gaithersburg, MD, ²IQVIA, Durham, NC
Background/Purpose: We evaluated the real-world frequency and severity of flares and associated costs 1 year post diagnosis in a US cohort with newly diagnosed SLE.Methods:…
Abstract Number: 2253 • 2019 ACR/ARP Annual Meeting
Comparing Patient and Provider Perspectives on Long Term Biologic Use and Tapering in Stable, Well-Controlled Rheumatoid Arthritis
Patrick Webster¹, Nicole Wilson ², Christina Payne ¹, Kelly Shields ³ and Tarun Sharma ¹, ¹Allegheny Health Network, Pittsburgh, PA, ²Medicine Institute Research, Bioinformatics, Pittsburgh, PA, ³Highmark Data Science, Pittsburgh
Background/Purpose: The 2015 American College of Rheumatology (ACR) and 2013 European League Against Rheumatology (EULAR) guidelines for management of rheumatoid arthritis (RA) conditionally recommend consideration…
Abstract Number: 937 • 2019 ACR/ARP Annual Meeting
Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Ankylosing Spondylitis: 48-Week Efficacy and Safety Results from a Phase 2b, Randomized, Blinded, Placebo-Controlled, Dose-Ranging Study
Désirée van der Heijde¹, Lianne Gensler ², Atul Deodhar ³, Xenofon Baraliakos ⁴, Denis Poddubnyy ⁵, Alan Kivitz ⁶, Marga Oortgiesen ⁷, Dominique Baeten ⁸, Nadine Goldammer ⁹, Jason Coarse ⁷, MK Farmer ⁷ and Maxime Dougados ¹⁰, ¹Leiden University Medical Center, Leiden, Netherlands, ²University San Francisco California, San Francisco, CA, ³Oregon Health & Science University, Portland, OR, ⁴Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany, ⁵Charité - Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany, Berlin, Germany, ⁶Altoona Center for Clinical Research, Duncansville, PA, ⁷UCB Pharma, Raleigh, NC, USA, Raleigh, NC, ⁸UCB Pharma, Brussels, Belgium, Brussels, ⁹UCB Pharma, Monheim, Germany, Monheim, Germany, ¹⁰Cochin Hospital, Paris, France
Background/Purpose: The monoclonal antibody bimekizumab potently and selectively neutralizes both IL-17A and IL-17F. We report the 48-week efficacy and safety of bimekizumab in patients (pts)…
Abstract Number: 2340 • 2019 ACR/ARP Annual Meeting
Treatment of Interstitial Lung Disease and Airway Disease Complicated with Rheumatoid Arthritis
Takeshi Shoda¹, Tohru Takeuchi ², Takuya Kotani ², Koji Nagai ², Kennichiro Hata ², Shigeki Makino ² and Shigeki Arawaka ², ¹Yodogawa christian hospital / Osaka medical college, Osaka, Japan, ²Osaka medical college, Osaka, Japan
Background/Purpose: Interstitial lung disease (ILD) complicated with rheumatoid arthritis (RA) is detected in 27 to 67% of patients on high-resolution computed tomography (HRCT), and airway…

1
2
3
…
29
Next Page »